Sexton, BioSpherix collaborate to support cell & gene therapy needs

By The Science Advisory Board staff writers

June 12, 2020 -- Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.

Sexton's off-the-shelf fill system, the Sexton Biotechnologies AF-500, will be combined with BioSpherix' Cytocentric isolator technology to allow for rapid process development and implementation of good manufacturing practice fill-finish.

With the AF-500, systems are ready to ship so developers can immediately begin process development of small volume fill and finish with the equipment they plan to use at clinical scale. Adding BioSpherix to the mix gives the technology the ability to operate within a fully closed environment along with the ability to control temperatures to limit risks during cryopreservation, the firms said.


Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter